Regeneron Pharmaceuticals (NASDAQ:REGN) reported double-digit growth in its second-quarter financial performance, with key products EYLEA HD, DUPIXENT, and LIBTAYO reaching all-time quarterly sales highs. The company also completed its repayment of the Sanofi development balance, allowing it to record full profits from DUPIXENT and KEVZARA going forward.
The company has significant milestones ahead, including a November PDUFA date for cemdisiran for generalized myasthenia gravis and pivotal data expected for paroxysmal nocturnal hemoglobinuria treatments. Regeneron anticipates further developments in metabolic programs and initiation of pivotal studies for olatorepatide targeting obesity and type 2 diabetes.
DUPIXENT has achieved a $24 billion annualized revenue run rate, with significant potential for growth across various indications, including atopic dermatitis and asthma. Regeneron is also preparing for a potential launch of cemdisiran, having bolstered its neurology expertise as the product approaches regulatory review.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
